# NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed) (PAR-28-072)

**Plain-English Eligibility Score:** 80/100

| Field | Value |
|---|---|
| Opportunity number | PAR-28-072 |
| Title | NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed) |
| Agency | National Institutes of Health |
| Status | posted |
| Posted / open date | 2026-09-25 |
| Close date | 2029-11-16 |
| Award ceiling | n/a |
| Award floor | n/a |
| Estimated total funding | n/a |
| Funding category | Health |
| Eligible applicants | Public housing authorities/Indian housing authorities; Public and State controlled institutions of higher education; Others (see text field entitled "Additional Information on Eligibility" for clarification); State governments; Native American tribal organizations (other than Federally recognized tribal governments); Native American tribal governments (Federally recognized); Private institutions of higher education; Small businesses; Special district governments; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; County governments; City or township governments |
| Eligibility notes | Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH w |
| CFDA / Assistance listing | 93.867 |
| Summary | The purpose of NEI's Translational Research program (TRP) is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. The TRP will support the product development of biological, pharmaceutical, medical device, and/or combination therapies for any disease or disorder of the visual system.The TRP will utilize a bi-phasic, milestone-driven mechanism of award. The R61 phase can be up to two years and will support research that has demonstrated significant preliminary data but has not advanced to the level of clinical translation. The R33 phase can be up to four years and will support resea |
| Agency contact | NEI_extramural@nih.gov |

## Why this score
- Small businesses are listed as eligible applicants.
- Nonprofits are listed as eligible applicants.
- 1107 days until the deadline: enough time to prepare a strong application.

Source: Grants.gov (U.S. Department of Health and Human Services) (https://www.grants.gov/search-results-detail/360545). Last refreshed: 2026-11-03T18:08:06.385Z.
Data from Grants.gov. Always read the full notice of funding opportunity before applying. Informational only; not legal or grant-writing advice.